Decentrialz logo
  • HIPAA Compliant
  • ISO 27001 Certified
Find Trials
About UsContact
Become a Volunteer+1 877 705 1914

Status:

TERMINATED

Trial of Romidepsin and Bortezomib for Multiple Myeloma

Lead Sponsor:

Celgene

Conditions:

Multiple Myeloma

Eligibility:

All Genders

18+ years

Phase:

PHASE2

Brief Summary

This is a phase II, open-label, multicenter, dual-strata study designed to evaluate the efficacy and safety of IV romidepsin given in combination with IV bortezomib for multiple myeloma (MM) patients ...

Eligibility Criteria

Inclusion

  • Inclusion Criteria
  • Patients must fulfill all of the following criteria to be eligible for study participation:
  • Male or female patients aged ≥ 18 years old
  • Has given voluntary written informed consent before any study-related procedure not part of normal medical care, with the understanding that consent may be withdrawn by the patient at any time without prejudice to their future medical care
  • Previously diagnosed with multiple myeloma (MM) based on standard criteria as follows:
  • Major criteria:
  • Plasmacytomas on tissue biopsy.
  • Bone marrow plasmacytosis (\>30% plasma cells).
  • Monoclonal immunoglobulin spike on serum electrophoresis IgG \>3.5 g/dL or IgA \>2.0 g/dL; kappa or lambda light chain excretion \>1 g/day on 24 hour urine protein electrophoresis
  • Minor criteria:
  • Bone marrow plasmacytosis (10 to 30% plasma cells)
  • Monoclonal immunoglobulin present but of lesser magnitude than given under major criteria
  • Lytic bone lesions.
  • Normal IgM \<50 mg/dL, IgA \<100 mg/dL or IgG \<600 mg/dL
  • Any of the following sets of criteria will confirm the diagnosis of MM:
  • Any two of the major criteria
  • Major criterion 1 plus minor criterion 2, 3, or 4.
  • Major criterion 3 plus minor criterion 1 or 3.
  • Minor criteria 1, 2, and 3 or 1, 2, and 4.
  • Currently has MM with:
  • o Measurable disease, defined as a monoclonal immunoglobulin spike on serum electrophoresis of \>=1 gm/dL and/or urine monoclonal immunoglobulin spike of \>=200 mg/24 hours, or evidence of lytic bone disease
  • Eastern Cooperative Oncology Group (ECOG) performance status of ≤ 2
  • Life-expectancy \> 3 months
  • All women of childbearing potential must use an effective barrier method of contraception. Male patients should use a barrier method of contraception during the treatment period and for 3 months thereafter
  • Patients must meet the following laboratory criteria at Baseline (Day 1 of Cycle 1, before study drug administration):
  • Platelet count ≥ 100\*10\^9/L
  • Absolute neutrophil count ≥ 1.5\*10\^9/L
  • OR if the bone marrow is extensively infiltrated
  • Platelet count ≥ 75\*10\^9/L
  • Absolute neutrophil count ≥ 1.0\*10\^9/L
  • Patients must meet the following laboratory criteria at the Screening visit conducted within 14 days of enrollment (Day 1, Cycle 1):
  • o Aspartate transaminase/serum glutamic oxaloacetic transaminase (AST/SGOT) and alanine transaminase/serum glutamic pyruvic transaminase (ALT/SGPT) ≤ 3.0\*upper limit of normal (ULN)
  • Serum bilirubin ≤ 2.0\*ULN
  • Calculated or measured creatinine clearance: ≥30 mL/minute. Patient with a creatinine \>10mL/min and \<30 mL/min due to significant myelomatous involvement of the kidneys may be enrolled in the study after receipt of approval from the lead investigator and sponsor
  • Serum potassium ≥ 3.8 mmol/L
  • Serum magnesium \>1.8 mg/dL
  • Serum phosphorus ≥ lower limit of normal (LLN)
  • Exclusion Criteria
  • Patients are ineligible for entry if any of the following criteria are met:
  • Chemotherapy or radiotherapy within 4 weeks (6 weeks for nitrosoureas or mitomycin C) or thalidomide, lenalidomide, arsenic trioxide, bortezomib, or glucocorticosteroids within 3 weeks prior to the first dose of romidepsin
  • Prior major surgery within 3 weeks prior to the first day of treatment
  • Use of any investigational agent within 4 weeks of study entry
  • Prior therapy with romidepsin
  • Any known cardiac abnormalities such as:
  • Congenital long QT syndrome;
  • QTc interval ≥ 500 milliseconds;
  • Myocardial infarction within 6 months of Day 1. Subjects with a history of myocardial infarction between 6 and 12 months prior to the first day of cycle one who are asymptomatic and have had a negative cardiac risk assessment (treadmill stress test, nuclear medicine stress test, or stress echocardiogram) since the event may participate;
  • Other significant electrocardiogram (ECG) abnormalities including 2nd degree atrio-ventricular (AV) block type II, 3rd degree AV block, or bradycardia (ventricular rate less than 50 beats/min);
  • Symptomatic coronary artery disease (CAD), e.g., angina Canadian Class II-IV In any patient in whom there is doubt, the patient should have a stress imaging study and, if abnormal, angiography to define whether or not CAD is present;
  • An ECG recorded at screening showing evidence of cardiac ischemia (ST depression depression of ≥2 mm, measured from isoelectric line to the ST segment). If in any doubt, the patient should have a stress imaging study and, if abnormal, angiography to define whether or not CAD is present;
  • Congestive heart failure (CHF) that meets New York Heart Association (NYHA) Class II to IV definitions and/or ejection fraction \<40% by Multi Gated Acquisition Scan (MUGA scan) or \<50% by echocardiogram and/or MRI;
  • A known history of sustained ventricular tachycardia (VT), ventricular fibrillation (VF), Torsade de Pointes, or cardiac arrest unless currently addressed with an automatic implantable cardioverter defibrillator (AICD);
  • Hypertrophic cardiomegaly or restrictive cardiomyopathy from prior treatment or other causes;
  • Uncontrolled hypertension, i.e., blood pressure (BP) of ≥160/95; patients who have a history of hypertension controlled by medication must be on a stable dose (for at least one month) and meet all other inclusion criteria; or
  • Any cardiac arrhythmia requiring an anti-arrhythmic medication (excluding stable doses of beta-blockers)
  • POEMS syndrome (plasma cell dyscrasia with polyneuropathy, organomegaly, endocrinopathy, monoclonal protein (M-protein) and skin changes)
  • Plasma cell leukemia
  • Primary amyloidosis
  • Patients with a prior malignancy within the last 5 years (except for basal or squamous cell carcinoma, or in situ cancer of the cervix)
  • Severe hypercalcemia, i.e., serum calcium ≥14 mg/dL (3.5 mmol/L)
  • Known infection with human immunodeficiency virus (HIV), hepatitis B, or hepatitis C
  • Other concurrent severe and/or uncontrolled medical or psychiatric conditions.
  • Concomitant use of drugs that may cause a prolongation of the QTc
  • Concomitant use of CYP3A4 inhibitors
  • Patients who have hypersensitivity to bortezomib, boron or mannitol
  • Patients who are pregnant or breast-feeding
  • Patients with any significant history of non-compliance to medical regimens or unwilling or unable to comply with the instructions given to him/her by the study staff

Exclusion

    Key Trial Info

    Start Date :

    September 1 2008

    Trial Type :

    INTERVENTIONAL

    Allocation :

    ACTUAL

    End Date :

    March 1 2010

    Estimated Enrollment :

    32 Patients enrolled

    Trial Details

    Trial ID

    NCT00765102

    Start Date

    September 1 2008

    End Date

    March 1 2010

    Last Update

    November 25 2019

    Active Locations (12)

    Enter a location and click search to find clinical trials sorted by distance.

    Page 1 of 3 (12 locations)

    1

    Loma Linda University Cancer Center

    Loma Linda, California, United States, 92354

    2

    Desert Cancer Care, Inc

    Rancho Mirage, California, United States, 92270

    3

    Santa Barbara Hematology Oncology Medical Group, Inc.

    Santa Barbara, California, United States, 93105

    4

    James R Berenson, MD, Inc.

    West Hollywood, California, United States, 90069